Table 1.
Demographics and baseline clinical characteristics of patients with longitudinally extensive transverse myelitis (LETM) in neuromyelitis optica spectrum disorder (NMOSD).
| TCZ | Prednisone | p value | |
|---|---|---|---|
| Number of patients(N) | 19 | 22 | / |
| Age at onset (year, mean ± SD) | 44.74 ± 15.83 | 52.68 ± 15.74 | 0.077 |
| Sex (F/total, percent) | 16/19 (84.21%) | 17/22 (77.27%) | / |
| Anti-AQP4 (positive, percent) | 12/19 (63.16%) | 15/22 (68.18%) | / |
| Treatment in acute attacks | |||
| HDMP (≥ 500mg/day) | 17 (89.47%) | 20 (90.91%) | / |
| IVIG (0.4g/kg/d×5d) | 1 (5.26%) | 1 (4.55%) | / |
| HDMP+IVIG | 1 (5.26%) | 1 (4.55%) | / |
| Number of previous attacks (median, IQR) | 2.0 (1.0-3.5) | 3.0 (2.0-4.8) | 0.073 |
| Annualized relapse rate (mean ± SD) | 1.18 ± 0.96 | 1.07 ± 1.74 | 0.872 |
| Follow-up time (years, mean ± SD) | 1.33 ± 0.63 | 1.10 ± 0.51 | 0.116 |
| Concurrent involvement | |||
| Optic neuritis | 2 (10.53%) | 3 (13.64%) | |
| Symptomatic cerebral syndrome | 10 (52.63%) | 8 (36.36%) | |
| Acute brainstem syndrome | 1 (5.26%) | 1 (4.55%) | |
| Score at onset of the acute attack | |||
| EDSS (median, IQR) | 7.0 (3.5-8.0) | 7.0 (3.1-8.0) | 0.979 |
| HAI (median, IQR) | 7.0 (1.0-8.0) | 7.0 (1.0-9.0) | 0.592 |
| mRS (median, IQR) | 4.0 (0.0-5.0) | 4.0 (1.0-5.0) | 0.703 |
| Pain (median, IQR) | 6.0 (3.5-7.0) | 7.0 (2.8-8.0) | 0.504 |
| FACIT-F (median, IQR) | 43.0 (16.0-47.0) | 41.5 (30.3-45.8) | 0.958 |
| ADL (median, IQR) | 25.0 (20.0-95.0) | 25.0 (15.0-90.0) | 0.700 |
| EQ-5D-3L (median, IQR) | 0.26 (0.16-0.73) | 0.20 (0.11-0.77) | 0.580 |
| FSS-Sensory function (median, IQR) | 2.0 (2.0-3.0) | 3.0 (2.0-3.0) | 0.314 |
| FSS-Bowel and bladder function (median, IQR) | 1.0 (0.50-3.0) | 1.0 (1.0-2.8) | 0.914 |
SD, Standard deviation; IQR, interquartile range.